Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

306 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Systematic review and network meta-analysis of overall survival comparing 3 mg/kg ipilimumab with alternative therapies in the management of pretreated patients with unresectable stage III or IV melanoma.
Dequen P, Lorigan P, Jansen JP, van Baardewijk M, Ouwens MJ, Kotapati S. Dequen P, et al. Among authors: lorigan p. Oncologist. 2012;17(11):1376-85. doi: 10.1634/theoncologist.2011-0427. Epub 2012 Sep 28. Oncologist. 2012. PMID: 23024154 Free PMC article. Review.
Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment.
Revicki DA, van den Eertwegh AJ, Lorigan P, Lebbe C, Linette G, Ottensmeier CH, Safikhani S, Messina M, Hoos A, Wagner S, Kotapati S. Revicki DA, et al. Among authors: lorigan p. Health Qual Life Outcomes. 2012 Jun 13;10:66. doi: 10.1186/1477-7525-10-66. Health Qual Life Outcomes. 2012. PMID: 22694829 Free PMC article. Clinical Trial.
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.
Kelderman S, Heemskerk B, van Tinteren H, van den Brom RR, Hospers GA, van den Eertwegh AJ, Kapiteijn EW, de Groot JW, Soetekouw P, Jansen RL, Fiets E, Furness AJ, Renn A, Krzystanek M, Szallasi Z, Lorigan P, Gore ME, Schumacher TN, Haanen JB, Larkin JM, Blank CU. Kelderman S, et al. Among authors: lorigan p. Cancer Immunol Immunother. 2014 May;63(5):449-58. doi: 10.1007/s00262-014-1528-9. Epub 2014 Mar 8. Cancer Immunol Immunother. 2014. PMID: 24609989 Free PMC article. Clinical Trial.
Improved survival with ipilimumab in patients with metastatic melanoma.
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Hodi FS, et al. Among authors: lorigan p. N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5. N Engl J Med. 2010. PMID: 20525992 Free PMC article. Clinical Trial.
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, Lorigan P, Kendra KL, Maio M, Trefzer U, Smylie M, McArthur GA, Dreno B, Nathan PD, Mackiewicz J, Kirkwood JM, Gomez-Navarro J, Huang B, Pavlov D, Hauschild A. Ribas A, et al. Among authors: lorigan p. J Clin Oncol. 2013 Feb 10;31(5):616-22. doi: 10.1200/JCO.2012.44.6112. Epub 2013 Jan 7. J Clin Oncol. 2013. PMID: 23295794 Free PMC article. Clinical Trial.
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A; KEYNOTE-006 investigators. Robert C, et al. Among authors: lorigan p. N Engl J Med. 2015 Jun 25;372(26):2521-32. doi: 10.1056/NEJMoa1503093. Epub 2015 Apr 19. N Engl J Med. 2015. PMID: 25891173 Free article. Clinical Trial.
Survival of patients with advanced metastatic melanoma: The impact of novel therapies.
Ugurel S, Röhmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Schadendorf D, Garbe C. Ugurel S, et al. Among authors: lorigan p. Eur J Cancer. 2016 Jan;53:125-34. doi: 10.1016/j.ejca.2015.09.013. Epub 2015 Dec 17. Eur J Cancer. 2016. PMID: 26707829 Review.
306 results